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Three diﬀerent models, a modiﬁed Chandler loop, roller pump, and a new ball valve model (Hemobile), were compared with
regard to intrinsic damage of blood components and activation of platelets. The Hemobile was used for testing of polymer tubes.
High ﬂow was not possible with the Chandler loop. The roller pump and the Hemobile could be adjusted to high ﬂow, but he
pump induced hemolysis. Platelet numbers were reduced in the roller pump and Chandler loop (P<0.05), but remained high
in the Hemobile. Platelet aggregation was reduced in all models. The Hemobile was applied for testing vascular graft materials,
and allowed diﬀerent circuits circulated simultaneously at 37◦C. ePTFE, Dyneema Purity UHMWPE ﬁber and PET ﬁber based
tubes, all showed hemolysis below 0.2% and reduced platelet count and function. Binding of ﬁbrin and platelets was higer on PET,
inﬂammatory markers were lowest on Dyneema Purity UHMWPE. We concluded that the Hemobile minimally aﬀects blood and
could be adjusted to high blood ﬂows, simulating arterial shear stress. The Hemobile was used to measure hemocompatibility of
graft material and showed Dyneema Purity UHMWPE ﬁber in many ways more hemocompatible than ePTFE and PET.
1.Introduction
The use of medical devices for temporary use or implan-
tation in the blood circulation has resulted in an increased
demand for evaluation of complications brought about
by these devices. This resulted also in-better deﬁned ISO
requirements for testing [1] One important and relevant
aspect of testing of medical devices is the condition of blood
exposed to the device. Anticoagulation and ﬂow conditions
must be as similar as possible as in the clinical setting
in order to achieve relevant test results. For some devices,
including grafts, stents, and catheters, this implies similar
anticoagulation treatment as used in clinical situations, but
also high ﬂow through or around the device to obtain
relevant shear stress conditions [2, 3]. However, in some
reports, blood was treated with other anticoagulants than in
clinical situations. In addition, test devices were incubated
under static conditions [4–7].
Flow models for testing may consist of animal models
or in vitro test systems. Animal models should be avoided
if equally quality results may be obtained in other ways. In
addition, animal blood has essential diﬀerences compared
with human blood, particularly with regard to clotting and
platelet function. Two types of in vitro ﬂow models (often
with human blood) have been used extensively: the modiﬁed
Chandler loop and the roller pump closed-loop system. The2 International Journal of Biomaterials
modiﬁed Chandler loop [8] consists of closed tubing partly
ﬁlled with air. On rotation, devices in the tubing repetitively
circulate through the air-liquid interface. Use of this system
may induce artefacts due to major forces applied to blood
elements and protein denaturation at the air-liquid interface
[9–11]. Another ﬂow model is the roller pump closed-loop
system. This model appeared eﬀective for short circulation
times[12–14],butintrinsicblooddamagereducessensitivity
and does not allow prolonged exposure to blood [15]. To
overcome the disadvantages of these models, the Hemobile
was constructed. It consists of a simple mechanical device
which generates a semicircular movement. In addition, the
tubing contains no air, and there is no mechanical device
compressing the tubing. In this way it was attempted to
reduce damage and activation and to simulate pulsatile ﬂow
in a frequency similar to the arterial circulation. The Hemo-
bile model was compared with the Chandler loop and roller
pump model for intrinsic damage to blood components and
activation of platelets. The Hemobile was further used in
testing tubular structures made of various polymers to show
its eﬀectiveness in determination of hemocompatibility by
means of in vitro circulation of human blood.
2.MaterialsandMethods
2.1. Blood Collection. Fresh human blood was obtained by
vena puncture with a 19 Gauge needle under low pressure
from ﬁve healthy adult volunteers and anticoagulated with
a clinical dose of heparin (1.5IU/mL) (Leo Pharmaceutical
Products BV, Weesp, The Netherlands).
2.2. Before Incubation. Before starting the experiment, cell
count (cell counter Medonic CA 530, Medonic, Sweden) and
platelet function analysis (Platelet Function Analyzer-100)
were performed and platelet aggregation was determined
by adding 50mMol ADP to a mixture of 500μL of blood
and 500μL of saline and with the use of a whole blood
aggregometer (Chrono Log Corp. aggregometer, Kordia Life
Sciences, Leiden, The Netherlands) to conﬁrm proper blood
quality relevant for this study and to provide baseline
characteristics.
2.3. Flow Models. Three circulation models were compared;
the modiﬁed Chandler loop, roller pump, and Hemobile
model (Figure 1). The principle of the modiﬁed Chandler
model is based on a chamber of air that remains on top
of a vertical rotating circular loop (De Spatel BV, Roden,
the Netherlands). The roller pump is a nonocclusive pump
for clinical use in extracorporeal circuits (St¨ ockert, Munich,
Germany). The Hemobile (Haemoscan BV, Groningen, the
Netherlands) consists of a cylinder, which is forced in
a semirotating movement. On this cylinder the circular
loop circuits can be positioned. Due to the semirotating
movement and the slowness of blood, a pulsating movement
of blood through the circuits is generated which mimics
pulsatile ﬂow. A ball valve ensures a directed ﬂow of up
to 40mL/min through 3mm tubing at 60beats/min, thus
creating shear stresses of 12dynes/cm2. Also, the ﬂow wave
formgeneratedbythemodelismorephysiologicalcompared
to the roller pump and Chandler model.
2.4. Study Design Model Validation. A comparative study
was performed to assess intrinsic blood damage for three
diﬀerent closed-loop circulation models, without any test
device in the circuit. Each set of experiments (three diﬀerent
circuits in triplicate) was performed ﬁve times with fresh
venous blood from a diﬀerent donor for each set. Due to
restrictions of the Chandler loop model, the ﬂow through
3mm tubing was limited to 25mL/min (6dynes/cm2)i n
all experiments. The ﬁrst set of experiments was performed
under circumstances of similar ﬂow (25mL/min) in all three
test systems.
The following sets of experiments (n = 4) were per-
formed with the roller pump and Hemobile at an exceeded
blood ﬂow of 40mL/min (12dynes/cm2), which resembles
shear stresses in the coronary blood circulation.
After these validation experiments, the Hemobile was
used to test the hemocompatibility of woven tubular
structures from polyester (PET) ﬁber and Dyneema Purity
UHMWPE ﬁber, in comparison with expanded polytetraﬂu-
oroethylene (ePTFE) tubes. Platelet function, thrombosis,
and hematology were tested according ISO10993/4.
2.5. Incubation. All experiments were performed with closed
PVC tubing circuits (Raumedic) with a length of 45cm
and an internal diameter of 3mm. The Chandler loop and
roller pump circuits contained Luer-lock connectors. The
Hemobile circuits were ﬁtted with a ball valve connector
(Halkey-Roberts, Street Petersburg, FL, USA). The roller
pump circuit was partially immersed in water, whereas the
Chandler loop and Hemobile were completely placed in an
oven (Figure 1). The temperature in all three circuits was
p e r m a n e n t l yk e p ta t3 7 ◦C. The circuits of the roller pump
and Hemobile were ﬁlled with 4.5mL of blood and the
circuits rotating on the Chandler loop system with 4.0mL
of blood and 0.5mL of air.
2.6. After Incubation. After one hour of circulation, the
circuits were emptied. Cell count, platelet function analysis,
and platelet aggregation measurements were performed on
thecirculatedblood,asdescribedabove.Therestoftheblood
wasmixedwith0.2MEDTAandcentrifugedat11,000×gfor
one minute. Plasma was used for analysis of thromboxane
B2 (TXB2), Thrombin-Antithrombin III (TAT) complexes,
elastase, and hemoglobin concentrations.
Activation of the arachidonic acid pathway in platelets
results in the release of the potent platelet aggregating
agent thromboxane A2, which is rapidly converted to the
inactive product TXB2. TXB2 was measured by means of
an enzyme immunoassay (Biotrak, Amersham, UK), based
on competition of labelled TXB2 with sample TXB2. In this
test the label is a peroxidase, which converts the substrate
tetramethylbenzidine, yielding a yellow colour which is
measured at 450nm by a spectrophotometer (Powerwave
200, Biotek Instruments, Winooski, VT, USA).
TAT was measured as an indication of coagulation activ-
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Figure 1: Schematic presentation of in vitro modiﬁed Chandler loop, Hemobile, and roller pump circulation model. All models could
contain a chamber in the circulation loop, containing a biomaterial or product for testing.
determined by means of TAT complexes in EDTA plasma.
AT A TE L I S Aw a sp e r f o r m e dw i t hc a p t u r ea n dd e t e c t i o no f
antibodies from Cederlane Laboratories (Hornby, Canada).
Release of polymorphonuclear (PMN) elastase in vivo is
a speciﬁc marker for inﬂammation reactions. Free in plasma,
elastase is rapidly neutralised by α1-antitrypsin inhibitor
to form a stable complex. Elastase was determined by
ELISA by means of capture antibody against human elastase
and labelled detection antibody against alpha1 antitrypsin
(Aﬃnity Biologicals, Ontario, Canada).
Complement activation was determined by ELISA based
on a mouse anti human C5-9 antibody (DAKO, Glostrup,
Denmark) and goat anti-C5 detection antibody (Quidel, San
Diego, CA, USA).
Free hemoglobin as an index for erythrocyte damage
w a sm e a s u r e da sd e s c r i b e db y H a r b o e[ 16] and using a
spectrophotometer (Power Wave 200). The emptied PVC
circuits and the incubated graft material were washed
with Tris-buﬀered saline (pH 7.4). Platelet adhesion onto
the surface of the circuits was measured by means of a
colorimetricassay,basedonthepresenceofacidphosphatase
in platelets [17]. Platelet binding was measured based on
the release of platelet acid phosphatase in Citrate buﬀer
(pH 5.4), containing p-nitrophenyl phosphatase and Triton
X100. Substrate conversion is proportional to the amount
of platelets, which was determined by a standard curve and
platelet counting.
Scanning electron microscopy (SEM) was achieved on
material ﬁxated in 2% glutaraldehyde in cacodylate buﬀer,
treatedwithosmiumtetraoxideincacodylatebuﬀerandgold
sputtered critical point dried samples. These were visualized
at 2kV (Jeol 6301 F, Jeol Ltd., Tokyo, Japan).
2.7. Statistical Analysis. Normally distributed variables were
reported as mean with standard deviation (SD). ANOVA was
performedforallbloodparameterstoassessanydiﬀerencein
blood celldamageor activation between the circuits.Posthoc
evaluation was performed by t-test.
3. Results
3.1. Whole Blood Assays at 25mL/min Flow. Platelet-count
was signiﬁcantly reduced by the roller pump and by the
modiﬁedChandlerloop,butnotbytheHemobile(Figure 2).
Platelet function was partially decreased in all systems, in
particular in the roller pump system. Platelet adhesion to the
PVC tubing was lowest in the Chandler loop (Table 1).
3.2. Plasma Assays. TXB2 and free hemoglobin were sig-
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Figure 2: Eﬀects of three circulation models on platelets. Platelet


























































Figure 3: Eﬀect of three types of graft on platelet function. Platelet
number and functions were similar after contact with vascular graft
materials made of ePTFE, PET or Dyneema Purity UHMWPE ﬁber.
Chandler loop and Hemobile circulation (Table 1). TAT was
similarly increased in all systems.
3.3. Results at 40mL/min Flow. Pump and Hemobile could
be applied at a ﬂow of 40 mL/min, which was not possible
with the Chandler model. Platelet number remained higher,
and hemolysis was lower in the Hemobile circuits (Table 2).
3.4. Application of the Hemobile in Thrombogenicity Testing.
Platelet count was reduced in the circuits containing a test
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Figure 4: Eﬀect of three types of graft on platelet binding (receptor
GpIIb). Platelet adhesion was lowest in the vascular grafts made of
Dyneema Purity UHMWPE ﬁber, as compared to ePTFE and PET.
ﬁber by approximately 30% following circulation compared
to baseline. Platelet function was reduced in all circuits to
a similar extent (Figure 3). Platelet binding based on the
adhesion of antibody against the platelet GpIIb receptor
showed increased values on PET, whereas Dyneema Purity
UHMWPE ﬁber had lowest GpIIb receptors (Figure 4). In
the ePTFE circuits, release of TXB2 and TAT was lowest,
whereaselastase,complementactivation,andhemolysiswere
lowest in Dyneema Purity UHMWPE ﬁber circuits (Table 3).
3.5.ScanningElectronMicroscopy. SEMphotoswer emadeof
all types of vascular graft materials. More detailed pictures
showed platelets and ﬁbrin usually separate and not as
a dense thrombus on the surface. Diﬀerences between
the 3 types of graft materials were not clear from these
pictures, although ePTFE seemed to remain more devoid of
deposition than PET and Dyneema Purity UHMWPE ﬁber
(Figure 5).
4. Discussion
Initial experimental blood circulation models with a roller
pump, already reﬁned in previous studies [13, 14, 18],
appeared eﬃcient, reliable, and cost-eﬀective to assess the
haemocompatibility of grafts before their clinical use. How-
ever, blood damage induced by the pump caused a limitation
of the exposure of the test object to circulating blood. The
modiﬁed Chandler loop model is currently most frequently
usedforthesepurposes[19,20].Itinduceslessblooddamage
than the roller pump but has two major disadvantages.
First, the continuous blood-air contact induces leukocyte
and platelet aggregation, protein denaturation [9–11], and
shear forces on particulate material, which can result in
detachment[21,22].Inourexperiments,indeedlessplatelets
were observed on tubing exposed to blood-air contact in
the Chandler loop than in the roller pump or Hemobile
circuit. The second disadvantage of the Chandler loop is
the limitation of blood circulation due to the requirement
to keep the air on top of the circuit. Air tends to circulate
with the tubing at higher circulation speed. Thus, our 3mm
tubing did not allow a blood ﬂow over 25mL/min, which is
half of the arterial ﬂow in the coronary system. At a ﬂow ofInternational Journal of Biomaterials 5
(a) (b)
(c)
Figure 5: Scanning Electron Microscopy. (a) PET ﬁber: platelets clusters and erythrocytes were observed attached to the ﬁbers. (b) Dyneema
PurityUHMWPEﬁberweave:separateplateletssomeerythrocytesandaproteinlayerwereobservedontheﬁbers.(c)ExpandedPTFE:small
clusters of platelet were observed.
Table 1: Activation markers in plasma after Chandler loop, roller pump and Hemobile blood circulation at 25mL/min.
Baseline Chandler Roller pump Hemobile
TxB2(pg/mL) 34 ±12 712 ±296 1222
∗±166 879 ± 167
TAT (μg/mL) 3.2 ±1.76 6 .7 ±21.56 5 .4 ±24.46 4 .3 ± 20.6
Hemolysis (gHb/L) 0.07 ±0.06 0.21 ±0.19 0.85
∗∗ ±0.14 0.21 ± 0.06
Platelet adhesion — 0.46# ±0.41 0.72 ±0.42 0.89 ± 0.53
∗P < 0.05, ∗∗P<0.01 compared to Chandler loop and Hemobile; #P < 0.05 compared to roller pump and Hemobile
TXB2: tromboxane B2; TAT: thrombin-antithrombin III.
25and 40mL/min, the Hemobile could be used and was less
traumatic for blood than the roller pump model.
It is well known that any type of foreign body mate-
rial can be thrombogenic by promoting the formation of
thrombinandplateletactivation,whichfacilitatesplateletsto
adhere and to express surface receptors (Gp IIbIIIa) of acti-
vated phase [23]. Platelet binding becomes then irreversible
and can promote more thrombus formation. Therefore,
proper testing of the characteristics of graft material is an
important issue in modulating blood interaction. The small
tubular system used in the present models allows multiple
tests with fresh human blood. The modiﬁed Chandler loop
and Hemobile can be easily loaded with a number of circuits
atatime.Fastscreeningofthrombogenicityofvasculargrafts
and other small medical devices is possible. The adjustable
ﬂow and shear and the pulsatility in the Hemobile renders it
in a model that allows standardised testing of these devices
at the cost of low intrinsic blood damage, while closely
mimicking the in vivo conditions. Our results indicated that
the changes in circulating blood are most of all dependent
on the material used in the test loop. Moreover a direct
comparison of material surfaces was possible by using blood
of the same donor for diﬀerent circuits.
ThefeasibilityoftheHemobilehasbeendemonstratedby
applying themodel inhemocompatibility studiesofdiﬀerent
vascular graft materials.
Woven tubes made of PET ﬁber and Dyneema Purity
UHMWPE ﬁber have been compared to commercially avail-
able ePTFE vascular graft. Our results showed that Dyneema
Purity UHMWPE ﬁber has in many ways better properties
thanePTFEbyloweractivationoftheinﬂammatoryresponse
and lower hemolysis.6 International Journal of Biomaterials
Table 2: Roller pump and Hemobile performed at 40mL/min blood circulation.
Baseline Roller pump Hemobile
Platelet number (10E9/L) 115 ±36 70 ±28 117 ±32
∗
Bleeding constant (sec) 72 ±7 108 ±20 99 ±21
Aggregation (slope) 18.7 ±7.16 .9 ±38 .7 ±4.7
Adhesion (10E6/cm2)— 0 .75 ±0.73 0.53 ±0.45
Hemolysis (gHb/L) 0.07 ±0.06 0.95 ±0.51 0.18 ±0.11
∗∗
∗P<0.05; ∗∗P<0.01 compared to roller pump.
Table 3: Activation markers in plasma after Hemobile circulation at 40mL/min in the presence of diﬀerent grafts (average ± SD).
Baseline ePTFE PET Dyneema Purity
TxB2 (pg/mL) 21 ±14 779 ±642 964 ±428 948 ±246
TAT (μg/mL) 0.7 ±0.77 3 .7 ±118 147.6 ±53 90.0 ±131
elastase (μg/mL) 0.32 ±0.35 4.36 ±5.27 3.00 ±3.01 2.85 ±2.97
C5b-9 (U/mL) 1.55 ±2.17 3.31 ±3.01 3.41 ±2.82 2.60 ±2.63
hemolysis (gHb/L) 0,02 ±0.01 0,14 ± 0.10 , 1 5 ±0.11 0,08 ±0.002
TXB2: thromboxane B2; TAT: thrombin-antithrombin III.
A limitation of in vitro models is mainly represented by
the absence of an endothelial layer in the circulating system.
Throughout the release of cytokines, the endothelium has a
major role in mediating the interplay between the injured
vessel wall and circulating blood cells [24–26]. This is
eﬀectuated by the release of cytokines and (anti)thrombotic
components as well as the expression of adhesion molecules.
The lacking of this character can somehow alter the like-
lihood of our experimental representation. Prior to use in
patients an animal model should prove the validity of the in
vitro data. Nevertheless, all the other elements depicting the
blood-graft phase boundary scene are present, while the use
of human blood from one donor in test and control circuits
is a major advantage for comparison of the materials.
Acknowledgments
The study was partly sponsored by DSM Biomedical,
Urmond, The Netherlands. The correspondence author
declares that none of the authors of the paper, have a direct
ﬁnancial relation with the commercial identity mentioned in
this paper that might lead to a conﬂict of interest.
References
[1] TC 194/WG9. ISO 10993-4:2002 Biological evaluation of
medicaldevices—Part4:selectionoftestsforinteractionswith
blood.
[2] K. Kawakami, Y. Harada, M. Sakasita, H. Nagai, M. Handa,
and Y. Ikeda, “A new method for continuous measurement of
platelet adhesion under ﬂow conditions,” Asaio Journal, vol.
39, no. 3, pp. M558–M560, 1993.
[3] V. Balasubramanian, E. Grabowski, A. Bini, and Y. Nemerson,
“Platelets, circulating tissue factor, and ﬁbrin colocalize in
ex vivo thrombi: real-time ﬂuorescence images of thrombus
formation and propagation under deﬁned ﬂow conditions,”
Blood, vol. 100, no. 8, pp. 2787–2792, 2002.
[4] V. I. Sevastianov and V. M. Parfeev, “Fatigue and hemocom-
patibility of polymer materials,” Artiﬁcial Organs, vol. 11, no.
1, pp. 20–25, 1987.
[5] M.Dadsetan,H.Mirzadeh,N.Shariﬁ-Sanjani,andP.Salehian,
“Invitrostudiesofplateletadhesiononlaser-treatedpolyethy-
lene terephthalate surface,” Journal of Biomedical Materials
Research, vol. 54, no. 4, pp. 540–546, 2001.
[6] S. F. Mohammad and D. B. Olsen, “Immobilized albumin-
immunoglobulin g for improved hemocompatibility of
biopolymers,” Asaio Transactions, vol. 35, no. 3, pp. 384–387,
1989.
[7] C. Beythien, W. Terres, and C. W. Hamm, “In vitro model
to test the thrombogenicity of coronary stents,” Thrombosis
Research, vol. 75, no. 6, pp. 581–590, 1994.
[8] A. B. Chandler, “In vitro thrombotic coagulation of blood: a
method for producing a thrombus,” Laboratory Investigation,
vol. 7, pp. 110–116, 1958.
[9] T. Thorsen, H. Klausen, R. T. Lie, and H. Holmsen, “Bubble-
induced aggregation of platelets: eﬀects of gas species, pro-
teins, and decompression,” Undersea & Hyperbaric Medicine,
vol. 20, no. 2, pp. 101–119, 1993.
[10] S. Ritz-Timme, N. Eckelt, E. Schmidtke, and H. Thomsen,
“Genesis and diagnostic value of leukocyte and platelet
accumulations around “air bubbles” in blood after venous air
embolism,” International Journal of Legal Medicine, vol. 111,
no. 1, pp. 22–26, 1998.
[ 1 1 ]R .M i l l e r ,V .B .F a i n e r m a n ,R .W ¨ ustneck, J. Kr¨ agel, and D.
V. Trukhin, “Characterisation of the initial period of protein
adsorption by dynamic surface tension measurements using
diﬀerent drop techniques,” Colloids and Surfaces A, vol. 131,
no. 1–3, pp. 225–230, 1998.
[ 1 2 ]D .A .W a n g ,J .J i ,C .Y .G a o ,G .H .Y u ,a n dL .X .F e n g ,
“Surface coating of stearyl poly(ethylene oxide) coupling-
polymer on polyurethane guiding catheters with poly(ether
urethane) ﬁlm-building additive for biomedical applications,”
Biomaterials, vol. 22, no. 12, pp. 1549–1562, 2001.
[13] S. H.J.Monnink,A.J.Van Boven, H.O. J.Peels etal., “Silicon-
carbide coated coronary stents have low platelet and leukocyte
adhesion during platelet activation,” Journal of Investigative
Medicine, vol. 47, no. 6, pp. 304–310, 1999.International Journal of Biomaterials 7
[14] G. Amoroso, A. J. Van Boven, C. Volkers, H. J. G. M. Crijns,
and W. Van Oeveren, “Multilink stent promotes less platelet
and leukocyte adhesion than a traditional stainless steel
stent: an in vitro experimental study,” Journal of Investigative
Medicine, vol. 49, no. 3, pp. 265–272, 2001.
[15] K. M¨ unch, M. F. Wolf, P. Gruﬀaz et al., “Use of simple and
complex in vitro models for multiparameter characterization
of human blood-material/device interactions,” Journal of Bio-
materials Science, Polymer Edition, vol. 11, no. 11, pp. 1147–
1163, 2000.
[16] M. Harboe, “A method for determination of hemoglobin in
plasma by near-ultraviolet spectrophotometry,” Scandinavian
Journal of Clinical and Laboratory Investigation,v o l .1 1 ,n o .1 ,
pp. 66–70, 1959.
[17] P. Bellavite, G. Andrioli, P. Guzzo et al., “A colorimetric
methodforthemeasurementofplateletadhesioninmicrotiter
plates,” Analytical Biochemistry, vol. 216, no. 2, pp. 444–450,
1994.
[18] J. Mulvihill, T. Crost, J. L. Renaux, and J. P. Cazenave,
“Evaluation of haemodialysis membrane biocompatibility by
parallel assessment in an ex vivo model in healthy volunteers,”
Nephrology Dialysis Transplantation, vol. 12, no. 9, pp. 1968–
1973, 1997.
[19] K. Christensen, R. Larsson, H. Emanuelsson, G. Elgue, and A.
Larsson,“Eﬀectsonbloodcompatibilityinvitrobycombining
a direct P2Y12 receptor inhibitor and heparin coating of
stents,” Platelets, vol. 17, no. 5, pp. 318–327, 2006.
[20] S. Sinn, T. Scheuermann, S. Deichelbohrer, G. Ziemer, and H.
P. Wendel, “A novel in vitro model for preclinical testing of
the hemocompatibility of intravascular stents according to iso
10993-4,” Journal of Materials Science, vol. 22, pp. 1521–1528,
2011.
[21] W. C. Culp, T. R. Porter, T. C. McCowan et al., “Microbubble-
augmented ultrasound declotting of thrombosed arteriove-
nous dialysis grafts in dogs,” Journal of Vascular and Interven-
tional Radiology, vol. 14, no. 3, pp. 343–347, 2003.
[22] C. G´ omez-Su´ arez, H. J. Busscher, and H. C. Van Der Mei,
“Analysisofbacterialdetachment fromsubstratumsurfacesby
the passage of air-liquid interfaces,” Applied and Environmen-
tal Microbiology, vol. 67, no. 6, pp. 2531–2537, 2001.
[23] M. H. Jeong, W. G. Owen, M. E. Staab et al., “Porcine model
of stent thrombosis: platelets are the primary component
of acute stent closure,” Catheterization and Cardiovascular
Diagnosis, vol. 38, no. 1, pp. 38–43, 1996.
[24] R. Komatsu, M. Ueda, T. Naruko, A. Kojima, and A. E. Becker,
“Neointimal tissue response at sites of coronary stenting in
humans: macroscopic, histological, and immunohistochemi-
cal analyses,” Circulation, vol. 98, no. 3, pp. 224–233, 1998.
[25] H. M. M. Van Beusekom, D. M. Whelan, S. H. Hofma et al.,
“Long-term endothelial dysfunction is more pronounced after
stenting than after balloon angioplasty in porcine coronary
arteries,” Journal of the American College of Cardiology, vol. 32,
no. 4, pp. 1109–1117, 1998.
[26] P. K. Shah, “Plaque disruption and coronary thrombosis: new
insight into pathogenesis and prevention,” ClinicalCardiology,
vol. 20, no. 12, pp. II38–II44, 1997.